Selgantolimod

Generic Name: Selgantolimod

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₁₄H_₂₀FN_₅O

CAS Number: 2004677-13-6

Unique Ingredient Identifier: RM4GJT3SMQ

Background: Selgantolimod is under investigation in clinical trial NCT03491553 (Safety, Tolerability and Antiviral Activity of Selgantolimod in Virally-suppressed Adults With Chronic Hepatitis B).

Associated Conditions: -

Associated Therapies: -

Clinical Trials

Study of Oral TLR8 Agonist Selgantolimod on HBsAg in Participants With Both Chronic Hepatitis B and HIV

Phase 2

Recruiting

Conditions: Hepatitis B
HIV Infections

Interventions: Drug: Selgantolimod
Drug: Placebo

First Posted Date: 2022-09-22

Last Posted Date: 2024-12-05

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 48

Registration Number: NCT05551273

Locations: 🇺🇸
Alabama CRS, Birmingham, Alabama, United States
🇺🇸
UCSD Antiviral Research Center CRS, San Diego, California, United States
🇺🇸
University of California, San Francisco HIV/AIDS CRS (801), San Francisco, California, United States

and more 36 locations

Prev
1
Next

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy